GLP-1 Weight-Loss Drugs Being Tested on Overweight Cats

Two U.S. biotech companies are developing GLP-1 weight-loss treatments for overweight cats, signaling a potential expansion of the drug class into pet medicine. This development aligns with broader changes in the $200 billion U.S. pet economy and could open new markets for pharmaceutical firms.

By Elsa Ohlen,Carolin Roth · CNBC · July 18, 2026, 05:00 UTC

GLP-1 Weight-Loss Drugs Being Tested on Overweight Cats

Tickers: $AXTN $LLY $NVS

Topics: animal health GLP-1 pet medicine weight loss drugs

Read the full article at CNBC

More Health news

Eli Lilly Shares Rise Following Positive Clinical Trial Results for Retatrutide and Foundayo Motley Fool · November 12, 2026, 17:15 UTC
Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC